Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac by Year
Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — International reported YoY (%) (%)
Pfizer Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac: 34.0% in FY2025, up 3.0 pts from a year earlier.
Where the FY2025 figure comes from
“|| Vyndaqel family (e) | 6,380 | 5,451 | 17% | 16% | 3,834 | 3,547 | 8% | 2,546 | 1,904 | 34% | 30%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac — ATTR-CM) — International reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 34.0% | +3.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗ |
| FY2024 | Dec 31, 2024 | 31.0% | +10.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗ |
| FY2023 | Dec 31, 2023 | 21.0% | +12.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 9.0% | -55.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
| FY2021 | Dec 31, 2021 | 64.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗ |
| FY2019 | Dec 31, 2019 | 91.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗ |
Cite this data
StockData. (2026). Pfizer Vyndaqel Family (Vyndaqel / Vyndamax / Vynmac (%), annual FY2019–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/vyndaqel-yoy-intl
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.